DGX – Quest Diagnostics Incorporated
Healthcare | Diagnostics & Research
Key Statistics
AI Monthly Analysis Report
Comprehensive Investment Analysis of Quest Diagnostics Incorporated (DGX)
Publication Date: December 06, 2025
Company Overview
Quest Diagnostics Incorporated (NYSE: DGX), headquartered in Secaucus, New Jersey, is a leading player in the Diagnostics & Research industry, firmly positioned within the healthcare sector. Founded in 1967, Quest Diagnostics provides a comprehensive range of diagnostic testing and services, both domestically and internationally. Its operations include clinical testing, anatomic pathology testing, and other diagnostic information services under the Quest Diagnostics brand, alongside associated brands like AmeriPath and Dermpath Diagnostics.
Quest Diagnostics serves a diverse client base, including physicians, hospitals, health plans, and pharmaceutical companies, leveraging an extensive network of laboratories and patient service centers. The company’s ongoing commitment to delivering accurate and timely diagnostic information ensures it remains a critical component of the healthcare ecosystem.
52-Week Price Performance Analysis
52-Week Price Performance Chart
Over the past 52 weeks, Quest Diagnostics’ stock has exhibited a bullish trend, moving from approximately $150 to its current price of $182.46, marking a considerable gain of 17.55%. The stock has demonstrated higher highs and higher lows, which indicates strong investor sentiment.
Key Technical Indicators:
- 52-Week High: $197.55
- 52-Week Low: $148.70
- Current Price: $182.46
The price chart reveals essential support and resistance levels. The $160 mark acts as a formidable support level, having been tested multiple times throughout the year. Resistance is noted around the $190 level, where the stock previously faced selling pressure.
- Fifty-Day Moving Average: $183.966
- Price in Relation to Moving Average: Currently, the stock price is slightly below this moving average, indicating a cautious approach in the short term.
Recent trading has seen the stock consolidate within the $182-$190 range, hinting at investor indecision. A breakout above $190 could signal further upside potential, while a drop below the moving average might suggest a shift in market sentiment.
Financial Performance and Metrics
Quest Diagnostics has showcased impressive financial performance, with total revenues approximating $10.85 billion in the last fiscal year, contributing to an EBITDA of around $2.14 billion.
Financial Highlights:
- Revenue: $10.85 billion
- EBITDA: $2.14 billion
- Diluted EPS (Q3 2025): $2.60 (up 13% YoY)
- Revenue Growth (Q3 2025): 13.1% increase from the previous year
The company’s outlook is bolstered by strong fundamentals, with analysts projecting a revenue range between $10.96 billion and $11.00 billion for the full year of 2025. The adjusted EPS guidance is anticipated to be between $9.76 and $9.84, further emphasizing the company’s robust earning potential.
With 111,242,362 shares outstanding and about 4.41% sold short (4,294,155 shares), the perception of Quest Diagnostics among shareholders remains predominantly optimistic, as indicated by the relatively low short interest.
Recent News and Developments
Recent developments reflect Quest Diagnostics’ proactive approach to market opportunities:
-
Third Quarter 2025 Performance: The company reported a solid 13.1% increase in revenue year-on-year, driven by innovations in clinical diagnostics and ongoing expansion into the consumer health sector. This growth prompted an upward adjustment of its annual revenue forecast.
-
Strategic Initiatives: Quest reported the establishment of a joint venture with Corewell Health, aimed at enhancing laboratory service accessibility in Michigan. Additionally, the company garnered FDA Breakthrough Device Designation for its Haystack MRD test, marking a significant advancement in colorectal cancer diagnostics.
-
Stock Performance: Reflecting its positive trajectory, Quest Diagnostics stock reached an all-time high of $191.87 on October 20, 2025, indicating a 29.83% increase over the past year.
These developments suggest that Quest Diagnostics is well-positioned to capture growth in the evolving healthcare landscape, supported by its innovative offerings and strong market presence.
Market Sentiment and Analyst Recommendations
Market sentiment surrounding Quest Diagnostics appears cautiously optimistic. Although specific recommendation keys are lacking, the data suggests favorable analyst outlooks, with varying price targets reflecting potential growth.
Analyst Consensus:
- Target High Price: $215.00
- Average Target Price: $197.31
- Target Low Price: $166.00
- Median Target Price: $199.00
Barclays has reiterated an “Equal-Weight” recommendation with an average one-year price target of $191.40, indicating a potential upside of 5.77% from the latest closing price.
A majority of analysts appear to cluster their forecasts around the mid-point of potential value fluctuations, signaling a consensus that maintains a bullish tone towards Quest Diagnostics’ stock performance. The current share price of $182.46 is positioned strategically below these price targets, suggesting that investors may find meaningful entry points in the near term.
Conclusion
In summary, Quest Diagnostics Incorporated stands as a resilient competitor in the healthcare diagnostics sector, demonstrating strong financial performance, strategic growth initiatives, and positive technical indicators. While the stock has exhibited upward momentum, potential investors should remain aware of the consolidation phase currently underway. The future outlook remains promising, with significant upside potential indicated by analysts’ price targets, alongside moderate risks associated with the current consolidation and market sentiment.
As the healthcare landscape evolves, Quest Diagnostics’ commitment to innovation and excellence will be instrumental in shaping its trajectory. Investors should keep an eye on upcoming developments, market dynamics, and earning reports for a comprehensive view of this promising healthcare giant.
| Metric | Value |
|---|---|
| Market Cap | $20.4b |
| Total Debt | $6.4b |
| Total Cash | $435.0m |
| Shares Outstanding | 111.2m |
| Float Shares | 110.7m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.
📅 Report Generated: Recently updated